Log in to search using one of your social media accounts:

 

Protective effects of the caffeine against neurodegenerative diseases.

Protective effects of the caffeine against neurodegenerative diseases. Curr Med Chem. 2017 Oct 09;: Authors: Tellone E, Galtieri A, Russo A, Ficarra S Abstract Caffeine is one of the most consumed stimulant of the central nervous system. Similar to those of other stimulants, its effects are to improve brain activity and stimulate cognition learning and memory. Caffeine affects the brain by acting mainly as a non-selective blocker of the adenosine receptors (A1, A2A, A2B, and A3). The purpose of this review article is to provide an overview on the neurobiochemical impact of caffeine, focusing on the ability of the drug to effectively counteract several neurodegenerative disorders such as Alzheimer's, Parkinson's, Huntington's diseases, Multiple sclerosis and Amyotrophic lateral sclerosis and Epilepsy. What emerges is a significant therapeutic and prophylactic potentiality of caffeine because of its antioxidant activity combined with multiple molecular targets. Moreover, it is striking to note that a molecule such as caffeine, appeared in the land plants few billion years ago may be an efficient drug for cells of more recent evolutionary origin. PMID: 28990513 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research

Related Links:

Date: Tuesday, 05 22, 2018; Speaker: Dr. Ellen Sidransky , NHGRI; Dr. Ari Zimran, Hebrew University of Jerusalem Hadassah Medical School ; Building: Building 10 (Clinical Center); Lipsett Auditorium ; CME Credit
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Thursday, 05 31, 2018; Speaker: Gerald David Podskalny, DO, MPHS, Cross Disciplinary Team Leader, Food and Drug Administration (FDA); Building: Building 10 (Clinical Center); 7C101; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
BACKGROUND: Parkinson's disease demonstrates a spectrum of motor and non-motor symptoms. Falling is common and disabling. Current medical management shows minimal impact to reduce falls or fall-related risk factors, such as deficits in gait, strength, and ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Condition:   Parkinson Disease Intervention:   Drug: Ioflupane I 123 Sponsor:   Julie Gurwell Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Interventions:   Drug: IRL790;   Drug: Placebo Sponsor:   Integrative Research Laboratories AB Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Epilepsy Intervention:   Sponsors:   Epilepsy Foundation of America;   The Epilepsy Study Consortium;   UCB Biopharma S.P.R.L. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
"Understanding the Role of Hypoxia inducible factor during neurodegeneration for new therapeutics opportunities". Curr Neuropharmacol. 2018 Jan 10;: Authors: Merelli A, Rodriguez JCG, Folch J, Regueiro MR, Camins A, Alberto L Abstract Neurodegeneration (NDG) is linked with the progressive loss of neural function with intellectual and/or motor impairment. Several diseases affecting older individuals, including Alzheimer's disease, Amyotrophic Lateral Sclerosis, Huntington's disease, Parkinson's disease, stroke, Multiple Sclerosis and many others, are the most relevant disorders associated wit...
Source: Current Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Neuropharmacol Source Type: research
Authors: Matilla-Dueñas A, Corral-Juan M, Rodríguez-Palmero Seuma A, Vilas D, Ispierto L, Morais S, Sequeiros J, Alonso I, Volpini V, Serrano-Munuera C, Pintos-Morell G, Álvarez R, Sánchez I Abstract More than 600 human disorders afflict the nervous system. Of these, neurodegenerative diseases are usually characterised by onset in late adulthood, progressive clinical course, and neuronal loss with regional specificity in the central nervous system. They include Alzheimer's disease and other less frequent dementias, brain cancer, degenerative nerve diseases, encephalitis, epilepsy, geneti...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
CONCLUSIONS: Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies. CBD pre-clinical demonstration of antiepileptic activity is supported by recent clinical studies in human epileptic subjects resistant to standard antiepileptic drugs showing its potential use in children and young adults affected by refractory epilepsy. Evidence for use of CBD in PD is still not supported by sufficient data whereas only a few studies including a small number of patients are available. ...
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Tags: CNS Neurol Disord Drug Targets Source Type: research
This article provides an overview of burden of neurological diseases in Canada to set the stage for the in-depth systematic reviews of the 14 priority neurological conditions presented in subsequent articles in this issue. PMID: 27153747 [PubMed - as supplied by publisher]
Source: Neurotoxicology - Category: Neurology Authors: Tags: Neurotoxicology Source Type: research
More News: ALS | Alzheimer's | Antidoxidants | Brain | Caffeine | Chemistry | Epilepsy | Huntington's Disease | Learning | Multiple Sclerosis | Neurology | Parkinson's Disease | Universities & Medical Training